Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), today announced new data from
the Phase 3 MAESTRO-NASH trial demonstrating broad treatment
effects of resmetirom on noninvasive tests that may be used to
monitor NASH with liver fibrosis. The noninvasive testing data and
multiple additional abstracts from the MAESTRO program are being
presented at the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting, taking place in Boston from
November 10-14, 2023.
Resmetirom is a liver-directed thyroid hormone receptor (THR)-β
agonist oral therapy that is designed to target key underlying
causes of NASH. It is the only investigational therapy for NASH
that has achieved both fibrosis improvement and NASH resolution
primary endpoints in a Phase 3 trial.
In MAESTRO-NASH, resmetirom treatment helped patients with NASH
with significant fibrosis (F2/F3) as diagnosed on liver biopsy
achieve improvements in liver enzymes, magnetic resonance
imaging-proton density fat fraction (MRI-PDFF), magnetic resonance
elastography (MRE), FibroScan Vibration Controlled Transient
Elastography (VCTE), FibroScan Controlled Attenuation Parameter
(CAP), and the Enhanced Liver Fibrosis (ELF) test. Resmetirom also
reduced levels of LDL cholesterol and other lipids that are
associated with heart disease.
Rohit Loomba, M.D., Chief of the Division of Gastroenterology
and Hepatology at University of California San Diego School of
Medicine and lead author of the new MAESTRO-NASH analysis, stated,
“These new data from MAESTRO-NASH highlight the importance of
noninvasive tests in the care pathway for NASH with significant
liver fibrosis and further improves our understanding of
resmetirom’s liver-directed efficacy as a THR-β agonist. In our
analyses, resmetirom-mediated reduction in liver fat as measured by
MRI-PDFF, a noninvasive imaging test, was the strongest predictor
of both NASH resolution and fibrosis improvement on biopsy. This
suggests that reducing liver fat with a THR-β agonist may resolve
the underlying hepatitis that drives the disease and reverse or
halt the fibrosis progression that leads to negative patient
outcomes.”
Becky Taub, M.D., Chief Medical Officer and President of
Research & Development of Madrigal, stated, “It is encouraging
to see such a broad and consistent treatment response with
resmetirom across multiple noninvasive tests, from simple
blood-based tests that are widely used in clinical practice today
to advanced imaging tests that will play a larger role in future
care pathways for NASH. If resmetirom receives accelerated
approval, clinicians will have many opportunities to highlight
treatment response for their patients over time; even something as
readily measurable as an improvement in ALT or LDL can be highly
motivating for patients and support treatment adherence.”
A significant majority (>70%) of patients treated with
resmetirom 100 mg had a ≥30% MRI-PDFF response. A ≥30% MRI-PDFF
reduction was strongly associated with NASH resolution (96% of
patients) and fibrosis improvement (88% of patients). Median
reduction in MRI-PDFF was 52% overall in this group.
Resmetirom is an investigational therapy and has not been
approved by the FDA or any other regulatory authority. In September
2023, the FDA granted Priority Review for the new drug application
(NDA) seeking accelerated approval of resmetirom for the treatment
of NASH with liver fibrosis and assigned a Prescription Drug User
Fee Act date for resmetirom of March 14, 2024.
Artificial Intelligence-Based Analyses of MAESTRO-NASH
Biopsy Results
A second oral presentation from the MAESTRO program examined the
use of an artificial intelligence (AI) biopsy reading method
(HistoIndex Second Harmonic Generation “qFibrosis” score) to
measure the effect of resmetirom on fibrosis on serial liver biopsy
using both continuous and quantitative scoring. In this analysis,
AI-based reading of the biopsies reinforced the primary results
from the central pathologists: measurements of fibrosis change
using qFibrosis on either a continuous or categorical scale
demonstrated a clear improvement and less worsening in fibrosis
among resmetirom-treated patients as compared with placebo-treated
patients after 52 weeks. A late-breaking poster examining another
AI-based biopsy reading method (PathAI “AIM-NASH”) also
recapitulated the MAESTRO-NASH primary endpoint results and showed
a high degree of alignment with pathologists on NASH component
scoring.
Full Listing of Resmetirom Data Presentations at
AASLD
Multiple resmetirom and Madrigal health economics outcomes
research abstracts will be presented at the AASLD Liver
Meeting:
- Oral presentation: “Relationship of Non-Invasive Measures with
Histological Response in Patients with Nonalcoholic Steatohepatitis
and Fibrosis: 52-Week Data from the Phase 3 MAESTRO-NASH Trial”
[Monday, November 13 at 8:30 AM. Presenter: Rohit Loomba]
- Oral presentation: “Artificial Intelligence to Measure Fibrosis
Change on Liver Biopsy in MAESTRO-NASH: A Phase 3 Serial Liver
Biopsy Study in 966 Patients with NASH Treated with Resmetirom or
Placebo” [Sunday, November 12 at 11:00 AM. Presenter: Stephen
Harrison]
- Late-Breaking poster: “Artificial Intelligence-Based
Measurement of NASH Histology (AIM-NASH) Recapitulates Primary
Results from Phase 3 Study of Resmetirom for Treatment of
NASH/MASH” [Presenter: Janani Iyer]
- Poster of Distinction: “Resmetirom Treatment Helps Restore
Thyroid Hormone Levels in Patients with Nonalcoholic
Steatohepatitis: 52-Week Data from the Phase 3 MAESTRO-NASH Trial”
[Presenter: Stephen Harrison]
- Poster: “Resmetirom Improves the Atherogenic Lipid/Lipoprotein
Profile in Patients with Nonalcoholic Steatohepatitis: 52-Week Data
from the Phase 3 MAESTRO-NASH Trial” [Presenter: Naim
Alkhouri]
- Poster: “The Next Generation of HepQuant Tests Measure
Reduction in Risk for Clinical Events in Compensated NASH Cirrhosis
Subjects Treated with Resmetirom” [Presenter: Michael McRae]
- Poster: “Understanding the Incremental Costs of Nonalcoholic
Steatohepatitis and Diabetes Using Electronic Health Records and
Closed Claims Data” [Presenter: Jesse Fishman]
- Poster: “Characterizing the Management of Patients with NASH
(With Versus Without Cirrhosis) in Real-World Clinical Practice:
Rare Assessment by Hepatologists and Low Frequency of Imaging”
[Presenter: Christina Qian]
About the Resmetirom Phase 3 Program
Resmetirom is a liver-directed THR-β agonist oral therapy that
is designed to target key underlying causes of NASH.
Madrigal is currently conducting multiple Phase 3 clinical
trials to evaluate the safety and efficacy of resmetirom for the
treatment of NASH:
- The pivotal MAESTRO-NASH (Significant
Fibrosis) study includes a 52-week biopsy assessment to
support accelerated approval and an ongoing 54-month outcomes study
designed to generate confirmatory data that, if positive, will help
verify resmetirom’s clinical benefit and support full approval.
Positive topline results from the study were reported in December
2022.
- MAESTRO-NASH Outcomes (Compensated Cirrhosis)
evaluates progression to liver decompensation events in patients
with well-compensated NASH cirrhosis treated with resmetirom versus
placebo. A positive outcome is expected to support the full
approval of resmetirom for noncirrhotic NASH and expand the
eligible patient population for resmetirom with an additional
indication in patients with compensated NASH cirrhosis.
- The MAESTRO-NAFLD-1 (Safety) study was
designed to noninvasively evaluate the safety and tolerability of
resmetirom and provide a larger safety database to support
regulatory benefit-risk assessment. Positive topline results from
the study were reported in January 2022 and the primary publication
appeared in Nature Medicine. MAESTRO-NAFLD-OLE, an open-label
active treatment extension of MAESTRO-NAFLD-1, is ongoing to
collect additional safety data in patients with noncirrhotic NASH
and patients with well-compensated NASH cirrhosis.
Data from the 52-week first 1,000 patient portion of
MAESTRO-NASH, together with data from MAESTRO-NAFLD-1,
MAESTRO-NAFLD-OLE, Phase 2 and Phase 1 data, including safety
parameters, form the basis for Madrigal’s subpart H submission to
FDA for accelerated approval of resmetirom for treatment of NASH
with liver fibrosis.
About NASH
Nonalcoholic steatohepatitis (NASH) is a more advanced form of
nonalcoholic fatty liver disease (NAFLD). NASH is a leading cause
of liver related mortality and an increasing burden on healthcare
systems globally. Additionally, patients with NASH, especially
those with more advanced metabolic risk factors (hypertension,
concomitant type 2 diabetes), are at increased risk for adverse
cardiovascular events and increased morbidity and mortality.
Once patients progress to NASH with significant fibrosis
(F2/F3), the risk of adverse liver outcomes increases dramatically.
NASH is rapidly becoming the leading cause of liver transplantation
in the U.S. There are currently no FDA-approved therapies available
for the treatment of NASH.
NASH is also known as “metabolic dysfunction-associated
steatohepatitis (MASH)” following a change in disease nomenclature
introduced by hepatology medical societies in 2023.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a
clinical-stage biopharmaceutical company pursuing novel
therapeutics for nonalcoholic steatohepatitis (NASH), a liver
disease with high unmet medical need. Madrigal’s lead candidate,
resmetirom, is a liver-directed THR-β agonist oral therapy that is
designed to target key underlying causes of NASH. For more
information, visit www.madrigalpharma.com.
Forward Looking Statements
This communication includes “forward-looking statements” made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, that are based on Madrigal’s beliefs
and assumptions and on information currently available to it, but
are subject to factors beyond its control. Forward-looking
statements reflect management’s current knowledge, assumptions,
judgment and expectations regarding future performance or events.
Forward-looking statements include: all statements that are not
historical facts; statements referenced by forward-looking
statement identifiers, including the examples in the paragraph
below; resmetirom’s potential to be the first specialty therapy for
NASH patients with significant liver fibrosis; statements
concerning potential accelerated approval; and statements or
references concerning - the potential efficacy and safety of
resmetirom for noncirrhotic NASH patients and cirrhotic NASH
patients, possible or assumed future results of operations and
expenses, business strategies and plans (including ex-US.
Launch/partnering plans), research and development activities, and
the timing and results associated with the future development of
resmetirom, the timing and completion of projected future clinical
milestone events, including enrollment, additional studies,
top-line data and open label projections, plans, objectives, timing
and support for making for making a Subpart H (Accelerated Approval
of New Drugs for Serious or Life-Threatening Illnesses) submission
to FDA, projections or objectives for obtaining accelerated or full
approval for resmetirom, Madrigal’s primary and key secondary study
endpoints for resmetirom and the potential for achieving such
endpoints and projections, demonstrating clinical benefit to
support accelerated approval, the potential to support an
additional indication for resmetirom in patients with
well-compensated NASH cirrhosis, optimal dosing levels for
resmetirom and projections regarding potential NASH or NAFLD and
potential patient benefits with resmetirom, including future NASH
resolution, safety, fibrosis treatment, cardiovascular effects,
lipid treatment, and/or biomarker effects with resmetirom.
Forward-looking statements can be identified by terms such as
“accelerate,” “achieve,” “allow,” “anticipates,” “appear,” “be,”
“believes,” “can,” “confidence,” “continue,” “could,”
“demonstrates,” ”design,” “estimates,” “expectation,” “expects,”
“forecasts,” “future,” “goal,” “help,” “hopeful,” “inform,”
inform,” “intended,” “intends,” “may,” “might,” “on track,”
“planned,” “planning,” “plans,” “positions,” “potential,” “powers,”
“predicts,” ”predictive,” “projects,” “seeks,” “should,” “will,”
“will achieve,” “will be,” “would” or similar expressions and the
negatives of those terms.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to: the assumptions
underlying the forward-looking statements; risks of obtaining and
maintaining regulatory approvals, including, but not limited to,
potential regulatory delays or rejections; risks associated with
meeting the objectives of Madrigal’s clinical studies, including,
but not limited to Madrigal’s ability to achieve enrollment
objectives concerning patient numbers (including an adequate safety
database), outcomes objectives and/or timing objectives for
Madrigal’s studies; any delays or failures in enrollment, and the
occurrence of adverse safety events; risks related to the effects
of resmetirom’s mechanism of action; the achievement of enrollment
objectives concerning patient number, safety database and/or timing
for Madrigal’s studies; enrollment and trial conclusion
uncertainties; market demand for and acceptance of our products;
the potential inability to raise sufficient capital to fund ongoing
operations as currently planned or to obtain financings on terms
similar to those arranged in the past; the ability to service
indebtedness and otherwise comply with debt covenants; outcomes or
trends from competitive studies; future topline data timing or
results; our ability to prevent and/or mitigate cyber attacks,
unauthorized exfiltration of data or other security incidents; the
risks of achieving potential benefits in studies that includes
substantially more patients, and patients with different disease
states, than prior studies; the timing and outcomes of clinical
studies of resmetirom; and the uncertainties inherent in clinical
testing. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. Madrigal
undertakes no obligation to update any forward-looking statements
to reflect new information, events, or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events. Please refer to Madrigal’s submissions filed with the U.S.
Securities and Exchange Commission, or SEC, for more detailed
information regarding these risks and uncertainties and other
factors that may cause actual results to differ materially from
those expressed or implied. Madrigal specifically discusses these
risks and uncertainties in greater detail in the sections appearing
in Part I, Item 1A of its Annual Report on Form 10-K for the year
ended December 31, 2022, filed with the SEC on February 23, 2023,
as amended by our Form 10-K/A filed with the SEC on March 3, 2023,
and Part II, Item 1A of its Quarterly Reports on Form 10-Q for the
quarters ended June 30, 2023 and September 30, 2023, and as updated
from time to time by Madrigal’s other filings with the SEC.
Investor Contact Alex Howarth, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024